Patents by Inventor Ming Hsieh

Ming Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170058027
    Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.
    Type: Application
    Filed: May 16, 2016
    Publication date: March 2, 2017
    Applicant: AbbVie Inc.
    Inventors: Chengbin WU, Dominic J. AMBROSI, Chung-ming HSIEH, Tariq GHAYUR
  • Publication number: 20170022281
    Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
    Type: Application
    Filed: June 7, 2016
    Publication date: January 26, 2017
    Applicant: AbbVie Inc.
    Inventors: Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
  • Publication number: 20170027060
    Abstract: A method for forming electrode patterns on a substrate is disclosed. A layer of conductive materials is formed on the substrate, and a portion of the conductive materials is annealed by an exposing manner. The layer of conductive materials after being exposed includes an annealed first portion and an unannealed second portion. One of the annealed first portion or the unannealed second portion is removed from the substrate to form electrode patterns on the substrate.
    Type: Application
    Filed: December 11, 2015
    Publication date: January 26, 2017
    Inventors: TE-JEN TSENG, CHIA-MING HSIEH, TZU-HSIANG LIN
  • Patent number: 9550986
    Abstract: The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: January 24, 2017
    Assignee: AbbVie Inc.
    Inventors: Feng Dong, Lorenzo Benatuil, Jijie Gu, Chung-Ming Hsieh
  • Publication number: 20170008514
    Abstract: A hybrid controller unit includes a detection module, a gear-hold module, a gear-skip module, and an optimizing module. The detection module is structured to detect a deceleration event. The gear-hold module is structured to determine whether a certain gear of a transmission should be maintained for a certain period of time in order to optimize power regeneration during the deceleration event. The gear-hold module is also structured to generate a gear-hold request. The gear-skip module is structured to determine whether the transmission should skip a gear in order to optimize power regeneration during the deceleration event. The gear-skip module is also structured to generate a gear-skip request. The optimizing module is structured to receive the gear-hold request and the gear-skip request and generate a transmission command to be sent to a transmission control unit for actuation.
    Type: Application
    Filed: February 23, 2015
    Publication date: January 12, 2017
    Applicant: Cummins, Inc.
    Inventors: Mahesh Madurai-Kumar, Tung-Ming Hsieh, Pinak Tulpule, Praveen Chitraduraga Muralidhar, Martin T. Books
  • Publication number: 20170002075
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 5, 2017
    Inventors: Jijie GU, Chung-Ming HSIEH, Zhen WU, Enrico L. DiGIAMMARINO, Feng LUO, Gerard B. FOX, John E. HARLAN, Martin SCHMIDT, Ralf LOEBBERT, Reinhold MUELLER, Ulrich EBERT, Volker NIMMRICH
  • Publication number: 20160380085
    Abstract: A method of manufacturing a semiconductor device includes receiving a FinFET precursor including a fin structure formed between some isolation regions, and a gate structure formed over a portion of the fin structure; removing a top portion of the fin structure on either side of the gate structure; growing a semiconductive layer on top of a remaining portion of the fin structure such that a plurality of corners is formed over the fin structure; forming a capping layer over the semiconductive layer; performing an annealing process on the FinFET precursor to form a plurality of dislocations proximate to the corners; and removing the capping layer.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: I-CHIH CHEN, CHIH-MING HSIEH, FU-TSUN TSAI, YUNG-FA LEE, CHIH-MU HUANG
  • Patent number: 9515576
    Abstract: A bridge circuit and a short-circuit protection method thereof. The bridge circuit includes an input power unit, a converter unit, a first capacitor, a second capacitor, a detection unit and a bridge inverter unit. The input power unit includes a first electrode and a second electrode. The converter unit is coupled to the input power unit. The first capacitor includes a first terminal and a second terminal. The second capacitor includes a first terminal and a second terminal. The bridge inverter unit includes a plurality of switches and is coupled to the converter unit, the first capacitor, the second capacitor, the detection unit and the second electrode. The detection unit issues a short-circuit signal to a control unit when the detection unit detects a current variation on the second capacitor.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 6, 2016
    Assignee: VOLTRONIC POWER TECHNOLOGY CORP.
    Inventors: Yi-Sheng Yuan, Chun-Juan Zhan, Juor-Ming Hsieh
  • Publication number: 20160347850
    Abstract: The present invention encompasses antagonist anti-CD40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-CD40 antibodies. In certain embodiments, antibodies of the invention neutralize human CD40 (hCD40) activity. Antibodies, or antibody portions, of the invention are useful for detecting CD40 and for inhibiting CD40 activity, e.g., in a human subject suffering from a disorder in which CD40 activity is detrimental.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Lorenzo Benatuil, Bradford L. McRae, Maria A. Argiriadi, Chung-Ming Hsieh
  • Publication number: 20160337722
    Abstract: A battery sensor with addressing mode and detection mode capability comprising a processor, an input interface, an output interface, an addressing channel and a detection channel; the processor connected to at least one battery parameter detection circuit; the addressing channel used a series connection manner to connect with a series connection input interface of the input interface, the processor and a series connection output interface of the output interface; a first communication interface of the input interface and a second communication interface of the output interface can be parallel connected to the processor by the detection channel; wherein the battery sensor can execute a battery addressing mode by the addressing channel, and the battery sensor can execute a battery parameter detection mode by the detection channel.
    Type: Application
    Filed: March 22, 2016
    Publication date: November 17, 2016
    Inventors: HUNG-MING HSIEH, HUNG-CHUN CHIEN, YUNG-HAO PENG
  • Patent number: 9495034
    Abstract: A touch panel is provided. The touch panel includes: a substrate, wherein the substrate includes a viewing region and a border region at an edge of the viewing region; a patterned transparent conductive layer formed on the substrate, wherein the patterned transparent conductive layer is formed on the viewing region and the border region, and the patterned transparent conductive layer has a touch sensitive function; and a patterned metal layer formed on the border region, wherein the patterned metal layer includes a contact region and a trace region connecting to the contact region, and at least a portion of the contact region overlaps with the patterned transparent conductive layer, wherein a shift range between the contact region and the patterned transparent conductive layer disposed on the border region adjacent to the contact region is smaller than about 150 ?m.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: November 15, 2016
    Assignees: INNOCOM TECHNOLOGY (SHENZHEN) CO., LTD., INNOLUX CORPORATION
    Inventors: Chieh-Yu Chao, Canone Chen, Jia-Ming Hsieh, Wei-Lun Liao
  • Patent number: 9493568
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 15, 2016
    Assignee: AbbVie Inc.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Chung-Ming Hsieh, Jennifer Perez
  • Patent number: 9481736
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 1, 2016
    Assignee: AbbVie, Inc.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • Patent number: 9481735
    Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: November 1, 2016
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
  • Patent number: 9469688
    Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
  • Patent number: 9469689
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • Patent number: 9458244
    Abstract: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: October 4, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Chung-Ming Hsieh
  • Publication number: 20160280230
    Abstract: In a detecting method for performing driving safety evaluation regarding a state of a driver of a vehicle, a detecting system: collects physiological data of the driver; performs the driving safety evaluation based on the physiological data to determine whether the state of the driver is unsuitable for operating the vehicle; and when it is determined that the state of the driver is unsuitable for operating the vehicle, triggering an interference action that includes one of outputting an alert, preventing the vehicle from starting up and a combination thereof.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Inventor: Feng-Ming Hsieh
  • Publication number: 20160272703
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 22, 2016
    Inventors: Chung-ming HSIEH, Carrie GOODREAU, Tariq GHAYUR, Achim MOELLER, Sahana BOSE
  • Patent number: 9450093
    Abstract: Some embodiments of the present disclosure provide a method of manufacturing a semiconductor device including receiving a FinFET precursor including a fin structure formed between isolation regions, and a gate structure formed over a portion of the fin structure such that a sidewall of the fin structure is in contact with a gate spacer of the gate structure; patterning the fin structure to comprise a pattern of at least one upward step rising from the isolation region; forming a capping layer over the fin structure, the isolation region, and the gate structure; performing an annealing process on the FinFET precursor to form at least two dislocations along the upward step; and removing the capping layer.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: September 20, 2016
    Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
    Inventors: I-Chih Chen, Chih-Ming Hsieh, Fu-Tsun Tsai, Yung-Fa Lee, Chih-Mu Huang